Navigation Links
New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease
Date:10/31/2011

, 4% placebo), hypertension (5% CIMZIA, 2% placebo), nasopharyngitis (5% CIMZIA, 1% placebo), back pain (4% CIMZIA, 1% placebo), pyrexia (3% CIMZIA, 2% placebo), pharyngitis (3% CIMZIA, 1% placebo), rash (3% CIMZIA, 1% placebo), acute bronchitis (3% CIMZIA,1% placebo), fatigue (3% CIMZIA, 2% placebo). Hypertensive adverse reactions were observed more frequently in patients receiving CIMZIA than in controls.  These adverse reactions occurred more frequently among patients with a baseline history of hypertension and among patients receiving concomitant corticosteroids and non-steroidal anti-inflammatory drugs.  Patients receiving CIMZIA 400mg as monotherapy every 4 weeks in RA controlled clinical trials had similar adverse reactions to those patients receiving CIMZIA 200mg every other week.  The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 5% for CIMZIA and 2.5% for placebo.

Please see full prescribing information at www.cimzia.com before prescribing.

For further Information:
Andrea Levin, Senior Manager, Communications & PR
(770) 970-8352, Andrea.Levin@ucb.com

Dena Koklanaris, Cooney/Waters Group
(212) 886-2228, DKoklanaris@cooneywaters.com

About UCB
UCB, Brussels, Belgium (www.ucb-usa.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

For fu
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
2. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
3. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
4. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
5. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
6. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
7. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
8. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
9. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
10. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
11. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015 Global physiotherapy ... USD 24.7 billion by 2022, according to a ... prevalence of neurological and musculoskeletal disorders are expected ... forecast period. The presence of efficient and effective ... the technologies coupled with implementation of favorable government ...
(Date:8/3/2015)... (NASDAQ: CYTR ), a biopharmaceutical research and development ... the three months ended June 30, 2015, and also ... for its clinical development programs. "The second ... Enrollment in our ongoing pivotal global Phase 3 clinical ... on track to be completed in the first quarter ...
(Date:8/3/2015)... Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... its Second Quarter 2015 Investor Conference Call and webcast ... The call will cover an update on Merrimack,s ... 2015 financials. A press release detailing the information to ... afternoon of Monday, August 10. Investors and the general ...
Breaking Medicine Technology:Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2
... (OTCQB: SCLR) announced today that it has launched several ... drug delivery platform, Controlled Delivery Technology ... under various private label brands across the country at ... product has been designed to deliver the full nutritional ...
... Feb. 16, 2012   Remedy Informatics, the leading provider ... Translational research, announced that its Founder and CEO, Gary ... R&D Informatics and Knowledge Management Track on Tuesday, Feb. ... 22 at Molecular Med TRI-CON Feb. 19-23, 2012, in ...
Cached Medicine Technology:SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012 2Remedy Informatics CEO, Gary Kennedy, to Speak at Molecular Med TRI-CON 2Remedy Informatics CEO, Gary Kennedy, to Speak at Molecular Med TRI-CON 3
(Date:8/3/2015)... ... August 03, 2015 , ... ... to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions that ... care costs. , Annually, more than 8.6 million adverse drug events are ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in ... patients in need. Most people know that general health emergencies, such as broken arms ... amount of people know where to turn to during a dental emergency. This is ...
(Date:8/3/2015)... Florida (PRWEB) , ... August 03, 2015 , ... ... for Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis ... , Fifty-five percent of respondents said they agreed or strongly agreed that the ...
(Date:8/3/2015)... ... , ... The U.S. Food and Drug Administration (FDA) recently approved a new ... which occurs naturally in the body and helps absorb and breakdown fat cells. Previously, ... body. These are invasive procedures and very expensive for most people. Now with Kybella, ...
(Date:8/3/2015)... ... ... Illinois Health & Science (IHS) has completed the purchase of IBA Molecular ... IBAM NA’s cyclotron sites and research and development facilities. , “We are ... as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and CEO ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2
... researchers from Stanford have identified the nitric oxide gas as ... resulting in the development of an embryo.He says,it begins with ... ,The research is based on the sex lives of ... in the Pacific Ocean just a few yards from Epel's ...
... flowing smoothly after angioplasty shows surprising success in early testing. ... the drug-coated stent. //In testing on 50 patients over 3 ... ,More than 2 million Americans undergo angioplasty annually, ... most of them if these promising results hold up in ...
... in arresting the dental plaque bacteria believed to be ... report at the American Association// for Dental Research annual ... produces hydrogen peroxide is the key to the antimicrobial ... associate professor of biochemistry at the University of Waikato, ...
... Scientists form Johns Hopkins University School of Medicine have recently ... in the brain that lets us stop smelling something, even ... in a recent issue of the journal Science show that ... receptor cells.The main job of these neurons is to detect ...
... Corp is close to signing a deal to acquire the ... fellow US drugmaker Abbott Laboratories Inc. An industry source who ... in the next few days to buy the stake in ... senior Abbott officials from the company’s regional office in singapore ...
... undergoing open heart surgery for patients in their mid-eighties ... and advisable for the elderly.// ,According to Dr. ... University ,open heart surgery, if indicated, is safe and ... and head of cardiac surgery at Southeastern Healthcare in ...
Cached Medicine News:Health News:The route to fertilization, 2Health News:Heart Surgery Is Getting Safer for the Old 2
... Oxygen Conservation Device. Bypass ... ,6200 Accessories: , OCD870C ... CGA 540 Regulator , OCD2001-18 ... Booklet , CP2140 Vertical M-6 ...
... Catheter with Accutrol is similar in design ... that it incorporates a temperature probe at ... temperature probe can accurately determine the patient's ... provides temperature accuracy comparable to a pulmonary ...
... These markers are available with 16 or 24 ... 6.5mm diameter, and an outer 9.5mm diameter. The markers ... in one single step for a 16 or 24 ... outer points on the cornea to achieve a precise ...
... Through A 1.0mm Incision., ,Special Direct Acting ... Improved ... Approach., ,Recessed Jaws For Improved Sub-Incisional Flap ... Jaws During Sterilization., ,Reusable, Autoclaveable, Guaranteed For ...
Medicine Products: